KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accumulated Expenses (2018 - 2025)

Aquestive Therapeutics has reported Accumulated Expenses over the past 8 years, most recently at $5.0 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $5.0 million for Q4 2025, down 14.86% from a year ago — trailing twelve months through Dec 2025 was $5.0 million (down 14.86% YoY), and the annual figure for FY2025 was $5.0 million, down 14.86%.
  • Accumulated Expenses for Q4 2025 was $5.0 million at Aquestive Therapeutics, down from $5.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for AQST hit a ceiling of $8.7 million in Q4 2021 and a floor of $3.3 million in Q1 2025.
  • Median Accumulated Expenses over the past 5 years was $5.6 million (2023), compared with a mean of $5.9 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 370.55% in 2021 and later crashed 39.46% in 2023.
  • Aquestive Therapeutics' Accumulated Expenses stood at $8.7 million in 2021, then fell by 8.8% to $8.0 million in 2022, then decreased by 18.45% to $6.5 million in 2023, then decreased by 9.08% to $5.9 million in 2024, then decreased by 14.86% to $5.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $5.0 million (Q4 2025), $5.1 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.